Molecular mechanism of cerebral edema improvement via IL-1RA released from the stroke-unaffected hindlimb by treadmill exercise after cerebral infarction in rats

J Cereb Blood Flow Metab. 2023 May;43(5):812-827. doi: 10.1177/0271678X231151569. Epub 2023 Jan 18.

Abstract

Cerebral edema following cerebral infarction can be severe and directly affect mortality and mobility. Exercise therapy after cerebral infarction is an effective therapeutic approach; however, the molecular mechanism remains unclear. Myokines such as interleukin-1 receptor antagonist (IL-1RA) are released during skeletal muscle contraction with effects on other organs. We hypothesized that myokine release during exercise might improve brain edema and confirmed the hypothesis using transient middle cerebral artery occlusion (tMCAO) model rats. Rats subjected to tMCAO were divided according to the severity of illness and further assigned to exercise and non-exercise groups. Treadmill exercises were performed at a speed of 2-8 m/min for 10 min from 1-6 days post-reperfusion after tMCAO. Exercise significantly reduced edema and neurological deficits in severely ill rats, with a reduction in aquaporin-4 (AQP4) expression in the ischemic core and increased blood IL-1RA release from the stroke-unaffected hindlimb muscle after tMCAO. Administration of IL-1RA into the lateral ventricles significantly reduced edema and AQP4 expression in the ischemic core. In conclusion, treadmill exercise performed in the early phase of stroke onset alleviated the decrease in blood IL-1RA following ischemic stroke. IL-1RA administration decreased astrocytic AQP4 expression in the ischemic core, suppressing brain edema.

Keywords: Aquaporin-4; IL-1RA; brain edema; exercise; myokine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aquaporin 4 / metabolism
  • Aquaporin 4 / therapeutic use
  • Brain Edema* / etiology
  • Brain Edema* / metabolism
  • Brain Ischemia*
  • Hindlimb / metabolism
  • Infarction, Middle Cerebral Artery / drug therapy
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Rats
  • Stroke* / drug therapy

Substances

  • Interleukin 1 Receptor Antagonist Protein
  • Aquaporin 4